Cortechs.ai | Quantitative MRI and prostate cancer

Quantitative MRI and prostate cancer

Quantitative MRI for Prostate Cancer Detection and Monitoring AI Theater Presentation and RSNA 2021

(SAN DIEGO, Nov. 28, 2021)Cortechs.ai, creators of the first volumetric MRI AI application for clinical use, NeuroQuant, will be presenting new findings regarding the use of Quantitative MRI for Prostate Cancer Detection and Monitoring at this year’s Radiological Society of North America (RSNA) conference in Chicago. The presentation by Dr. Tyler Seibert MD, PhD will take place on Wednesday, December 1, 2021 at 2 p.m. in the AI Theater of the McCormick Place Convention Center. 

Tyler Seibert MD, PhD is a board-certified radiation oncologist, clinical translational researcher at UC San Diego, and one of Cortechs.ai’s Medical Advisory Board members. Seibert is experienced in complex data analysis, including development, validation, and translation of novel methods in both biomedical imaging and genetics. Innovations like OnQ Prostate are navigating cancer detection with data and precision that benefits physicians like Seibert with their analysis capabilities.

My top priority is to improve precision diagnosis and treatment of prostate cancer through quantitative imaging,” said Dr Seibert, “Together with our partners, Cortechs.ai has the ability to impart real innovation in the oncology MRI field.”

OnQ Prostate is FDA-cleared post-processing software that supports improved detection of clinically significant prostate cancer. The software leverages an advanced diffusion MRI technique called Restriction Spectrum Imaging (RSI), powered by AI, to enable faster, more accurate identification of restricted diffusion. Cortechs.ai will be stationed at booth 4542 showcasing and demonstrating NeuroQuant, NeuroQuant MS, OnQ Prostate. In addition, OnQ Neuro, a recently FDA cleared device for automated brain tumor segmentation with RSI technology, will also be introduced. Schedule a meeting in advance with a clinical specialist or account manager by clicking here

To learn more about Cortech.ai at RSNA 2021, visit www.cortechs.ai/rsna. Fellow AI-powered partner Subtle Medical, a healthcare technology company with deep learning solutions will be close-by at booth 4538 and you can request a meeting here. Cortechs.ai and Subtle Medical are a powerful team that contributes to real, fast, and objective results with imaging software. Together, our technology drastically reduces scan time and analysis.

About Cortechs.ai

Cortechs.ai is the leader in radiology AI applications, using cutting-edge advances in medical imaging to revolutionize disease screening and early detection so patients can enjoy longer, better lives. The company develops and markets breakthrough medical device software that quantifies and tracks neurodegenerative diseases and assists in the detection of clinically significant cancer. Cortechs.ai’s industry-leading brain imaging analysis provides neurologists, radiologists, oncologists, and clinical researchers worldwide with a convenient and cost-effective means to quantify brain structures to help assess neurological conditions, such as Alzheimer’s disease, epilepsy, multiple sclerosis, brain trauma, and brain development abnormalities. The company has FDA-cleared products for use in the diagnosis of neurodegenerative and traumatic brain conditions and prostate cancer. Please visit www.cortechs.ai for further information and follow us on Twitter, LinkedIn, and Facebook.

More Resources

07/31/2025

Precision Without the Pressure: Smarter Brain Tumor Monitoring

Learn about NeuroQuant Brain Tumor 2.0 and how it assists clinicians by providing objective quantification and analysis of tumor changes over time.

07/30/2025

Cortechs.ai Announce Next-Gen NeuroQuant Brain Tumor: AI-Driven Metastasis & Meningioma Segmentation 

NeuroQuant Brain Tumor is the first FDA-cleared, cloud-native tool to offer automated volumetric segmentation for brain metastases, meningiomas, and gliomas.

07/28/2025

Longitudinal Assessment of Traumatic Brain Injury Using NeuroQuant®

A case study with Dr. Suzie Bash on NeuroQuant as a reliable, reimbursable, and efficient tool in the evaluation and follow-up of TBI.

07/24/2025

Understanding the Hippocampal Occupancy Score

One of the most frequently asked questions among customers is, “What does the Hippocampal Occupancy Score (HOC) represent within the Dementia Report?”

07/16/2025

Advancing Prostate MRI with Restriction Spectrum Imaging

Why is OnQ Prostate unique, and what makes it a game-changer for clinicians?

07/08/2025

Enhancing Neuroimaging Insights: LVV & ICV Quantification and Midline Shift Indexing with NeuroAlign CT

Time-sensitive and precise diagnostic imaging can mean the difference between rapid intervention and devastating outcomes.
Scroll to Top